Congress Report Says FDA Broke Protocols In Approval Of Biogen Alzheimer's Drug

WESTON (dpa-AFX) - The US Food and Drug Administration's approval process for Biogen's controversial Alzheimer's drug Aduhelm was 'rife with irregularities,' a congressional report said.Oversight

Related Keywords

,Carolyn Maloney ,Frank Pallone Jr ,Reform Committee ,Commerce Committee ,Drug Administration ,Central Nervous System Drugs Advisory Committee ,Reform Committee Chairwoman Carolyn Maloney ,Commerce Committee Chairman Frank Pallone ,Chairman Pallone ,Central Nervous System Drugs Advisory ,Congress ,Report ,Ways ,Broke ,Protocols ,Approval ,Biogen ,Lzheimer ,Drug ,